Published in Clin Cancer Res on September 16, 2013
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
Cancer immunotherapy: are we there yet? Exp Hematol Oncol (2013) 0.98
Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol (2013) 0.95
Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor. BMC Med Genomics (2014) 0.87
The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma. Curr Protoc Pharmacol (2014) 0.86
Distinct microbiological signatures associated with triple negative breast cancer. Sci Rep (2015) 0.83
Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease. Cancer Med (2016) 0.78
Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res (2015) 0.77
MicroRNA profiling of CD3+ CD56+ cytokine-induced killer cells. Sci Rep (2015) 0.75
AACR Cancer Progress Report 2015. Clin Cancer Res (2015) 0.75
Machine learning approaches to analyze histological images of tissues from radical prostatectomies. Comput Med Imaging Graph (2015) 0.75
The Evaluation of Liver Function and Surgical Influence by ICGR15 after Chemotherapy for Colorectal Liver Metastases. J Cancer (2016) 0.75
Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells. J Immunol Res (2015) 0.75
Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. Oncotarget (2017) 0.75
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Whole-genome sequencing and variant discovery in C. elegans. Nat Methods (2008) 31.92
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res (2012) 15.90
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Extending assembly of short DNA sequences to handle error. Bioinformatics (2007) 14.46
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
The genome sequence of Caenorhabditis briggsae: a platform for comparative genomics. PLoS Biol (2003) 13.32
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Colorectal cancer statistics, 2014. CA Cancer J Clin (2014) 12.86
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin (2004) 12.55
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin (2014) 11.09
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
De novo gene disruptions in children on the autistic spectrum. Neuron (2012) 9.69
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Complete Khoisan and Bantu genomes from southern Africa. Nature (2010) 9.06
A high-resolution map of human evolutionary constraint using 29 mammals. Nature (2011) 8.67
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest (2005) 8.45
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
International variation in prostate cancer incidence and mortality rates. Eur Urol (2012) 8.04
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov (2008) 7.64
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Breast cancer statistics, 2013. CA Cancer J Clin (2013) 7.35
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst (2003) 7.06
Analyses of deep mammalian sequence alignments and constraint predictions for 1% of the human genome. Genome Res (2007) 7.05
Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer (2007) 6.84
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Dynamics of chronic myeloid leukaemia. Nature (2005) 6.63
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol (2012) 6.37
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Breast cancer statistics, 2011. CA Cancer J Clin (2011) 6.12
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer (2002) 6.08
Viral discovery and sequence recovery using DNA microarrays. PLoS Biol (2003) 5.95
The genome of a songbird. Nature (2010) 5.90
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87